Viridian Therapeutics Files 8-K: Material Agreement Announced
Ticker: VRDN · Form: 8-K · Filed: Jul 30, 2025 · CIK: 1590750
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: VRDN
TL;DR
Viridian Therapeutics (VRDN) signed a big deal, more details to come.
AI Summary
Viridian Therapeutics, Inc. announced on July 30, 2025, that it entered into a Material Definitive Agreement. The company also disclosed information related to Regulation FD and filed financial statements and exhibits. Specific details of the agreement and financial figures were not provided in this initial filing.
Why It Matters
This filing indicates a significant development for Viridian Therapeutics, likely involving a new partnership, acquisition, or financing, which could impact its stock price and future operations.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could be positive or negative depending on the specifics not yet disclosed.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- July 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36483 (identifier) — Commission File Number
- 47-1187261 (identifier) — IRS Employer Identification Number
FAQ
What is the nature of the Material Definitive Agreement entered into by Viridian Therapeutics?
The filing does not specify the nature of the Material Definitive Agreement, only that one was entered into on or before July 30, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 30, 2025.
What is Viridian Therapeutics' state of incorporation?
Viridian Therapeutics, Inc. is incorporated in Delaware.
What is Viridian Therapeutics' Commission File Number?
Viridian Therapeutics, Inc.'s Commission File Number is 001-36483.
What other items are disclosed in this 8-K filing besides the material agreement?
This 8-K filing also includes disclosures related to Regulation FD and financial statements and exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 30, 2025 regarding Viridian Therapeutics, Inc.\DE (VRDN).